insights_auto
Why is CNSY up 23.32%?
Dive Deeperchevron_right
CNSY:NASDAQ
Cerenome, Inc.
$0.95
arrow_upward
+23.32%(+0.18) 1D
$0.91
arrow_downward
-3.81% (-0.036)bedtimeAfter hours
Closed: Nov 13, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CNSY...
Open
$0.81
High
$1.18
Low
$0.81
Mkt. cap
7.22M
Avg. vol.
1.25M
Volume
8.13M
52-wk high
$4.25
52-wk low
$0.43
EPS
-$4.42
Beta
1.49
Shares outstanding
7.59M
No. of employees
28
Open
$0.81
High
$1.18
Low
$0.81
Mkt. cap
7.22M
Avg. vol.
1.25M
Volume
8.13M
52-wk high
$4.25
52-wk low
$0.43
EPS
-$4.42
Beta
1.49
Shares outstanding
7.59M
No. of employees
28
News stories
From web sources and news partners
Mugglehead Investment Magazine
·
3 hours ago
Cerenome reports first CNSide revenue and details funding
Zacks
·
23 hours ago
Cerenome (CNSY) Reports Q3 Loss, Beats Revenue Estimates
Yahoo Finance
·
1 day ago
Cerenome (CNSY) Reports Q3 Loss, Beats Revenue Estimates
Profile
Cerenome, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Cerenome also commercialized a molecular diagnostic service, CNSide®. Wikipedia
About Cerenome, Inc.
CEO-
Employees28
Founded1996
HeadquartersHouston, Texas, United States
SectorHealth Care
IndustryBiotechnology
Websitecerenome.com